- Market Capitalization, $K 186,575,584
- Shares Outstanding, K 3,098,233
- Annual Sales, $ 26,617 M
- Annual Income, $ 3,196 M
- 60-Month Beta 0.50
- Price/Sales 6.95
- Price/Cash Flow 18.60
- Price/Book 9.98
|Period||Period Low||Period High||Performance|
| || |
+3.77 (+6.68%)since 09/15/21
| || |
+3.26 (+5.72%)since 07/15/21
| || |
+7.67 (+14.60%)since 10/15/20
Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI ® (durvalumab) demonstrated a statistically significant and clinically...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
While Novavax's (NVAX) COVID-19 vaccine shows potential, delay in regulatory filings in both the United States and Europe does not bode well for the stock.
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).
Sector ETF report for PPH
If authorized by the FDA, AstraZeneca's (AZN) AZD7442 would be the first long-acting cocktail antibody drug approved for COVID-19 prevention.
AstraZeneca has submitted a request to the US Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for prophylaxis of symptomatic...
NEW YORK (AP) — Stocks that moved sharply or traded heavily Monday:
LONDON (AP) — Pharmaceutical company AstraZeneca says it is buying U.S. drug developer Alexion in a deal worth $39 billion.
|Astrazeneca Plc ADR|
|Advisorshares Doubleline Value Equity ETF|
|GS Activebeta International ETF|
|ACWI Low Carbon Target MSCI ETF SPDR|
|Flexshares ESG & Climate Developed Markets Ex-US|
|IQ 500 International ETF|
|3rd Resistance Point||60.94|
|2nd Resistance Point||60.74|
|1st Resistance Point||60.48|
|1st Support Level||60.02|
|2nd Support Level||59.82|
|3rd Support Level||59.56|